Australia markets close in 4 hours 27 minutes

Bioventus Inc. (BVS)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
5.11+0.59 (+13.05%)
At close: 04:00PM EST
5.11 0.00 (0.00%)
After hours: 07:10PM EST
Full screen
Trade prices are not sourced from all markets
Previous close4.52
Bid5.05 x 1400
Ask5.64 x 1000
Day's range4.69 - 5.52
52-week range0.80 - 5.52
Avg. volume160,844
Market cap321.755M
Beta (5Y monthly)0.38
PE ratio (TTM)N/A
EPS (TTM)-2.56
Earnings date07 Nov 2023
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est4.83
  • GlobeNewswire

    Bioventus Agrees to Nationwide Contract with Aetna™ Medicare Advantage Plans for DUROLANE® for Knee Osteoarthritis

    DURHAM, N.C., Dec. 06, 2023 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, has agreed to a nationwide contract with Aetna™ Medicare Advantage plans. Beginning January 1, 2024, over 3 million Aetna™ Medicare Advantage plan members will have access to DUROLANE to treat knee osteoarthritis (OA) pain. DUROLANE, is a single-injection hyaluronic acid (HA)-based joint-fluid treatment for patients. DUROLANE will be one

  • Insider Monkey

    Bioventus Inc. (NASDAQ:BVS) Q3 2023 Earnings Call Transcript

    Bioventus Inc. (NASDAQ:BVS) Q3 2023 Earnings Call Transcript November 12, 2023 Operator: Thank you for standing by. My name is Dustin, and I will be your conference operator today. This time, I would like to welcome everyone to Bioventus Inc. Third Quarter 2023 Earnings Conference Call. [Operator Instructions] At this time, I’d like to turn […]

  • GlobeNewswire

    Bioventus Reports Third Quarter Financial Results; Raises Full Year 2023 Financial Guidance

    DURHAM, N.C., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or "the Company"), a global leader in innovations for active healing, today reported financial results for the three and nine months ended September 30, 2023. Q3 Financial Summary: Net Sales of $120.8 million, down $7.9 million, or 6.1%, year-over-year as reported (6.3% constant currency*). Excluding revenues from divested wound assets, underlying organic sales decreased $0.6 million, or 0.5% year-over-year